1. The document presents the discovery of JSI-124, a selective inhibitor of the JAK/STAT3 pathway, which was identified from screening a library of compounds for inhibition of STAT3 phosphorylation in cancer cells. 2. JSI-124 was found to reduce phospho-STAT3 levels in multiple human cancer cell lines and block STAT3 DNA binding and gene transcription, inhibiting tumor growth. 3. JSI-124 selectively targeted STAT3 signaling over other pathways and showed potent antitumor activity against human tumor xenografts in mouse models, demonstrating its potential as an anticancer therapeutic targeting the STAT3 pathway.